2 assets in In Situ Carcinoma

Therapeutic assets addressing In Situ Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer In Situ Carcinoma	OncoNano Medicine, Inc.	P1	CC (43)
Onm-501 In Situ Carcinoma	OncoNano Medicine, Inc.	P1	CC (43)